12-Jun-2026
Pulse Biosciences Shareholders Approve Board and Auditor Slate
TipRanks (Fri, 12-Jun 5:15 PM ET)
Pulse Bio to redeem remaining common stock warrants
Seeking Alpha News (Wed, 10-Jun 10:14 AM ET)
Pulse Biosciences Announces Redemption of Remaining 200% Warrants
TipRanks (Wed, 10-Jun 9:22 AM ET)
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Business Wire (Wed, 10-Jun 7:00 AM ET)
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Business Wire (Wed, 27-May 4:05 PM ET)
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Business Wire (Tue, 12-May 7:00 AM ET)
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Business Wire (Fri, 8-May 7:00 AM ET)
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Business Wire (Mon, 4-May 7:00 AM ET)
Business Wire (Sat, 25-Apr 1:00 PM ET)
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Business Wire (Mon, 20-Apr 7:00 AM ET)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Pulse Biosciences trades on the NASDAQ stock market under the symbol PLSE.
As of June 12, 2026, PLSE stock price declined to $24.37 with 388,650 million shares trading.
PLSE has a beta of 0.57, meaning it tends to be less sensitive to market movements. PLSE has a correlation of 0.01 to the broad based SPY ETF.
PLSE has a market cap of $1.69 billion. This is considered a Small Cap stock.
Last quarter Pulse Biosciences reported $401,000 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-19,000 and missed earnings estimates by -$.03.
In the last 3 years, PLSE traded as high as $28.53 and as low as $3.78.
The top ETF exchange traded funds that PLSE belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
PLSE has outperformed the market in the last year with a return of +50.6%, while the SPY ETF gained +24.1%. In the last 3 month period, PLSE beat the market returning +14.4%, while SPY returned +11.6%. However, in the most recent 2 weeks PLSE has underperformed the stock market by returning -2.5%, while SPY returned -1.9%.
PLSE support price is $25.61 and resistance is $28.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLSE shares will trade within this expected range on the day.